Major histocompatibility complex Class II-based therapy for stroke

• Published in: Brain circulation Vol. 7; no. 1; pp. 37 - 40
• Main Authors: Gonzales-Portillo, Bella, Lee, Jea-Young, Vandenbark, Arthur, Offner, Halina, Borlongan, Cesario
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.01.2021; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Apoptosis; Cell death; Cytokines; drmq; Inflammation; Major histocompatibility complex; mesenchymal stem cell; mitochondrial transfer; Review; stem cell therapy; Stem cells; Stroke; stroke therapy; Transplantation; mesenchymal stem cell; DRmQ; Cell death; stem cell therapy; mitochondrial transfer; cytokines; stroke therapy
• ISSN: 2394-8108; 2455-4626; 2455-4626
• DOI: 10.4103/bc.bc_16_21

This review discusses the potential of major histocompatibility complex (MHC) Class II constructs as stroke therapeutics. We focus on the delivery of MHC Class II construct, DRmQ, as a safe and effective treatment for ischemic stroke. DRmQ was observed to attenuate behavioral deficits and decrease microglia activation and proinflammatory cytokines, illustrating its ability to mitigate the secondary cell death following stroke. Similar anti-neuroinflammation treatments, such as transplantation of mesenchymal stem cells and mitochondrial transfers, are briefly discussed to provide further support that sequestration of inflammation stands as a robust therapeutic target for stroke.